JLJonathan W. Lo

Jonathan W. Lo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan W. Lo has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent manner

    by Jonathan W. Lo, Jan-Hendrik Schroeder, Luke B. Roberts, Rami Mohamed, Domenico Cozzetto, Gordon Beattie, Omer S. Omer, Ellen M. Ross, Frank Heuts, Geraldine M. Jowett, et al.

    The maintenance of intestinal homeostasis is a fundamental process critical for organismal integrity. Sitting at the interface of the gut microbiome and mucosal immunity, adaptive and innate lymphoid populations regulate the balance between commensal micro-organisms and pathogens. Checkpoint inhibitors, particularly those targeting the CTLA-4 pathway, disrupt this fine balance and can lead to inflammatory bowel disease and immune checkpoint colitis. Here, we show that CTLA-4 is expressed by innate lymphoid cells and that its expression is regulated by ILC subset-specific cytokine cues in a microbiota-dependent manner. Genetic deletion or antibody blockade of CTLA-4 in multiple in vivo models of colitis demonstrates that this pathway plays a key role in intestinal homeostasis. Lastly, we have found that this observation is conserved in human IBD. We propose that this population of CTLA-4-positive ILC may serve as an important target for the treatment of idiopathic and iatrogenic intestinal inflammation.


  • Open Access

    Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis

    by Jonathan W. Lo, Domenico Cozzetto, James L. Alexander, Nathan P. Danckert, Matthew Madgwick, Naomi Knox, Jillian Yong Xin Sieh, Marton Olbei, Zhigang Liu, Hajir Ibraheim, et al.

    Immune checkpoint inhibitors (CPIs) are a relatively newly licenced cancer treatment, which make a once previously untreatable disease now amenable to a potential cure. Combination regimens of anti-CTLA4 and anti-PD-1 show enhanced efficacy but are prone to off-target immune-mediated tissue injury, particularly at the barrier surfaces. To probe the impact of immune checkpoints on intestinal homoeostasis, mice are challenged with anti-CTLA4 and anti-PD-1 immunotherapy and manipulation of the intestinal microbiota. The immune profile of the colon of these mice with CPI-colitis is analysed using bulk RNA sequencing, single-cell RNA sequencing and flow cytometry. CPI-colitis in mice is dependent on the composition of the intestinal microbiota and by the induction of lymphocytes expressing interferon-γ (IFNγ), cytotoxicity molecules and other pro-inflammatory cytokines/chemokines. This pre-clinical model of CPI-colitis could be attenuated following blockade of the IL23/IFNγ axis. Therapeutic targeting of IFNγ-producing lymphocytes or regulatory networks, may hold the key to reversing CPI-colitis.


  • Open Access

    Microbiota-dependent expression of CTLA-4 by innate lymphoid cells restrains IFNγ dependent colitis

    by Jonathan Lo, Jan-Hendrik Schroeder, Gordon Beattie, Luke Roberts, Domenico Cozzetto, Omer Omer, Ellen Ross, Frank Heuts, Geraldine Jowett, Emily Read, et al.

    The maintenance of intestinal homeostasis is a fundamental process critical for organismal integrity. Sitting at the interface of the gut microbiome and mucosal immunity, adaptive and innate lymphoid populations regulate the balance between commensal micro-organisms and pathogens. Checkpoint inhibitors (CPI), particularly those targeting the CTLA-4 pathway, disrupt this fine balance and can lead to inflammatory bowel disease (IBD) and immune checkpoint colitis (CPI-C). Here, we show that CTLA-4 is expressed by innate lymphoid cells (ILC) and that its expression is regulated by ILC subset-specific cytokine cues in a microbiota-dependent manner. Genetic deletion or antibody blockade of CTLA-4 demonstrates that this pathway plays a key role in intestinal homeostasis and is conserved in human IBD and CPI-induced colitis (CPI-C). We propose that this population of CTLA-4-positive ILC may serve as an important target for the treatment of idiopathic and iatrogenic intestinal inflammation.

  • O32 The interleukin 22//neutrophil axis is associated with treatment resistance in ulcerative colitis

    by Polychronis Pavlidis, Anastasia Tsakmaki, Eirini Pantazi, Katherine Li, Domenico Cozzetto, Feifei Yang, Jonathan Lo, Elena Alberts, Ana Caroline Costa Sa, Umar Niazi, et al.

    Introduction Interleukin (IL) 22 is a key cytokine involved in regulation of epithelial function and its role in IBD remains highly controversial. Some studies indicate a protective role in epithelial regeneration, whereas other studies imply a pro-inflammatory role. Insights are now needed to improve of understanding of the functional role of this important cytokine and how its expression might impact patients with ulcerative colitis (UC). In this study, we have probed the clinical and functional significance of IL-22 responsive transcriptional modules and causal networks in diseased tissue of over 500 UC patients and in preclinical models of colitis. Methods We mapped the transcriptional landscape of human colonic epithelial 3D mini-gut organoids in response to treatment with IL22, and other pro-inflammatory cytokines. We tested the clinical significance of the IL22-regulated transcriptome by probing whole colonic biopsies from 550 ulcerative colitis (UC) patients from UNIFI clinical trial programme (patients with UC treated with ustekinumab, an anti-IL12p40 antibody). The functional role of IL22 regulated biological pathways were evaluated in pre-clinical models of UC. Results IL-22 regulated pro-inflammatory biological pathways involved in microbial recognition, cancer and immune cell chemotaxis. IL-22 was an especially potent regulator of the CXC family chemokines CXCL1, CXCL2, CXCL5, CXCL6 and CXCL8, which are all powerful neutrophil-selective chemokines. There was a positive correlation between the IL-22 transcriptional programme and the histological severity of inflammation (r=0.49, p+ neutrophils to the colon. Conclusions The interleukin 22/neutrophil axis is functionally important in colitis and is associated with treatment resistance in ulcerative colitis

  • Open Access

    A population of naive‐like CD4+ T cells stably polarized to the TH1 lineage

    by Jonathan W. Lo, Maria Vila de Mucha, Stephen Henderson, Luke B. Roberts, Laura E. Constable, Natividad Garrido‐Mesa, Arnulf Hertweck, Emilie Stolarczyk, Emma L. Houlder, Ian Jackson, et al.

    T‐bet is the lineage‐specifying transcription factor for CD4+ TH1 cells. T‐bet has also been found in other CD4+ T cell subsets, including TH17 cells and Treg, where it modulates their functional characteristics. However, we lack information on when and where T‐bet is expressed during T cell differentiation and how this impacts T cell differentiation and function. To address this, we traced the ontogeny of T‐bet‐expressing cells using a fluorescent fate‐mapping mouse line. We demonstrate that T‐bet is expressed in a subset of CD4+ T cells that have naïve cell surface markers and transcriptional profile and that this novel cell population is phenotypically and functionally distinct from previously described populations of naïve and memory CD4+ T cells. Naïve‐like T‐bet‐experienced cells are polarized to the TH1 lineage, predisposed to produce IFN‐γ upon cell activation, and resist repolarization to other lineages in vitro and in vivo. These results demonstrate that lineage‐specifying factors can polarize T cells in the absence of canonical markers of T cell activation and that this has an impact on the subsequent T‐helper response.


  • Open Access

    Immune checkpoint inhibitor-induced colitis is mediated by CXCR6+ polyfunctional lymphocytes and is dependent on the IL23/IFNγ axis

    by Jonathan Lo, Domenico Cozzetto, Zhigang Liu, Hajir Ibraheim, Jillian Sieh, Marton Olbei, James Alexander, Jesus Miguens Blanco, Matthew Madgwick, Hiromi Kudo, et al.

    Immune checkpoint inhibitors (CPIs) have revolutionised cancer treatment, with previously untreatable disease now amenable to potential cure. Combination regimens of anti-CTLA-4 and anti-PD-1 show enhanced efficacy but are prone to off-target immune-mediated tissue injury, particularly at the barrier surfaces. CPI-induced colitis is a common and serious complication. To probe the impact of immune checkpoints on intestinal homeostasis, mice were challenged with combination anti-CTLA-4/anti-PD-1 immunotherapy and manipulation of the intestinal microbiota. Colonic immune responses were profiled using bulk and single-cell RNA-sequencing and flow cytometry. CPI-colitis was dependent on the composition of the intestinal microbiota and was characterized by remodelling of mucosal lymphocytes with induction of polyfunctional lymphocyte responses characterized by increased expression of interferon-γ (IFNγ), other pro-inflammatory cytokines/chemokines (Il22, Il17a Ccl3, Ccl4 and Ccl9), cytotoxicity molecules (Gzmb, Gzma, Prf1, Nkg7) and the chemokine receptor Cxcr6. In comparison with mucosal lymphocytes in the steady state, polyfunctional lymphocytes from both CD4+ and CD8+ lineages upregulated costimulatory molecules and checkpoint molecules in CPI-colitis, indicating that these cells are tightly regulated. CPI-colitis was attenuated following depletion of effector lymphocytes or following blockade of the IL23/IFNγ axis. This study provides new mechanistic insights into CPI-colitis, identifying polyfunctional, cytotoxic lymphocytes as key mediators of disease. Therapeutic targeting of their effector response or regulatory networks, including the IL23/IFNγ axis likely holds the key to preventing and reversing CPI-colitis.


  • Open Access

    A population of CD4 + T cells with a naïve phenotype stably polarized to the T H 1 lineage

    by Jonathan W. Lo, Maria Vila de Mucha, Luke B. Roberts, Natividad Garrido-Mesa, Arnulf Hertweck, Joana F. Neves, Emilie Stolarczyk, Stephen Henderson, Ian Jackson, Jane K. Howard, et al.

    T-bet is the lineage-specifying transcription factor for CD4 + T helper type 1 (T H 1) cells. T-bet has also been found in other CD4 + T cell subsets, including T H 17 cells and T REG , where it modulates their functional characteristics. However, we lack information on when and where T-bet is expressed during T cell differentiation and how this impacts T cell function. To address this, we traced the ontogeny of T-bet-expressing cells using a fluorescent fate-mapping mouse line. We demonstrate that T-bet is expressed in a subset of CD4 + T cells with naïve cell surface markers and that this novel cell population is phenotypically and functionally distinct from conventional naïve CD4 + T cells. These cells are also distinct from previously described populations of memory phenotype and stem cell-like T cells. Naïve-like T-bet-experienced cells are polarised to the T H 1 lineage, predisposed to produce IFNγ upon cell activation, and resist repolarisation to other lineages in vitro and in vivo . These results demonstrate that lineage-specifying factors can function to polarise T cells in the absence of canonical markers of T cell activation and that this has an impact on the subsequent T helper response.

  • Open Access

    Checkpoint Inhibitor Induced Colitis is Dependent on the Microbiota and Activation of Cytotoxic Innate and Adaptive Lymphocytes

    by Jonathan Wai Pang Lo, Domenico Cozzetto, Jan-Hendrik Schroeder, Jillian Yong Xin Sieh, Omer Omer, Hajir Ibraheim, Polychronis Pavlidis, Jonathan Digby-Bell, James L. Alexander, Jesus Miguens Blanco, et al.

    Immune checkpoint inhibitors (CPI) have revolutionised cancer treatment, with previously untreatable disease now amenable to potential cure. Combination regimens of anti-CTLA4 and anti-PD-1 show enhanced efficacy but are prone to off target immune-mediated tissue injury, particularly at the barrier surfaces. We show that CPI-induced colitis is dependent on the composition of the intestinal microbiota and involves innate immune mechanisms. Single cell RNA sequencing identified remodelling of mucosal lymphocytes in CPI-induced colitis, including the emergence of polyfunctional, cytolytic responses in CD4+ T-cells and innate lymphoid cells (ILCs). Unexpectedly, colitis deteriorated following CD4+ T-cell depletion and was maintained in mice lacking adaptive immunity. We show that both human and mouse colonic ILCs express CTLA4, which is regulated by microbial and inflammatory cues, and is functionally important in restraining innate immune activation. We provide new mechanistic insights into immune regulation at the mucosal barrier and important implications for the treatment of CPI-induced autoimmunity.